2009
|
- Creation of the Asia-Pacific Division
- Acquisition of Wockhardt animal health and creation of Vétoquinol India
- Launching of Request, a group of European experts in anti-infectives
- Launching of the 3D communication campaign, that values the three therapeutic fields of the Group |
2008 :
|
- Acquisition of Ascor Chimici in Italy
- Creation of a development unit in Canada
- Acquisition of Viavet in Scandinavia
- Launch of Vetprofen® (anti-inflammatory)
- Launch of Rubénal (nephrology) |
2007 :
|
- Vétoquinol Unipessoal Lda created, 17th subsidiary of the group in Portugal.
- Launch of Alfaxan® (anesthetic) |
2006 :
|
- Vétoquinol’s presence on Asian market expanded with the acquisition of its South Korean distributor, Semyung Vet.
- Stock exchange listing, in the Eurolist market of Euronext Paris (Compartment B, mnemonics: VETO ; ISIN code FR0004186856).
- Acquisition of Vet Solutions, American independent veterinary company located in Fort Worth, Texas (United States) |
2005 :
|
Launch of Clavaseptin®, a palatable antibiotic for dogs and cats. |
2004 :
|
- Sales office opened in Shanghai, China. Biological research discontinued. Vétoquinol concentrates on developing curative products.
- Debut of company’s new strapline: "Sign of Passion" |
2003 :
|
- International launch of Propalin®, treatment for urinary incontinence in ovariectomised bitches. Marbocyl® is supplied in palatable tablets form.
- New research and development centre opens. |
2002 :
|
- Vétoquinol moves into the international market for the first time with the acquisition of Evsco and Tomlyn ranges in the USA.
- Launch of Prilium®, the 1st liquid ACE inhibitor for heart failure in dogs demonstrates new service levels to veterinarians including innovative drug development, first international scientific symposium and prescription training. |
2001 :
|
- Vétoquinol acquires Swiss group Chassot and expands its nutraceuticals range.
- Launches Aurizon®, a treatment for otitis in dogs. |
1999 :
|
Following acquisition of Webster in Canada, Vétoquinol is confirmed as a market leader. |
1998 :
|
Takeover of MECA in Germany. |
1995 :
|
In Europe, Vétoquinol launches Marbocyl®, a high quality antibiotic researched by Vétoquinol. Within three years, it becomes a major product in the market. |
1994 :
|
Acquisition of Immunovet in the USA. |
1992 :
|
Vétoquinol Mexico founded. Vétoquinol North America buys Austin and Dispar in Canada. |
1991 :
|
Vétoquinol acquires Antibioticos Pharma Vet in Spain, renamed Vétoquinol Especialidades Veterinarias. |
1990 :
|
Vétoquinol acquires Univet in the UK and founds Vétoquinol North America, Canada. They in turn acquire Multivet and MVE. |
1987 :
|
Vétoquinol launches Tolfedine®, an anti-inflammatory set to become the French market leader and acquires Psyphac in Belgium. |
1984 :
|
Galvet Ltd founded in Ireland. |
1980 :
|
R&D centre opened to provide technical support for Vétoquinol. |
1977 :
|
Vetam, the first overseas subsidiary, founded in the Netherlands. |
1975 :
|
New French laws introduced for veterinary products. Vétoquinol adapts to these becoming increasingly professionally aware. |
1962 :
|
Becomes "Vétoquinol S.A" , exclusively devoted to animal health. Facilities transfer from Lure, Haute Saône to Magny-Vernois. Étienne Frechin, son of Joseph Frechin and our current President, joins the company. |
1956 :
|
Production of medicines for human use is discontinued. |
1933 :
|
- Joseph Frechin founds the Laboratoires Biochimiques de l’Est, for human products, in Lure, Haute-Saone.
- He develops the first quinoline-based veterinary product: Vétoquinol. |
